The Chinese pharmaceutical company Techdow is taking its first steps in Spain. Its recent presentation, followed by the specialized health media and some of the financial press, has demonstrated its arrival in the Spanish market with a medicine called Inhixa, a compound based on heparin, with anticoagulant properties.

The company came to Spain in 2017, and it is already present in Switzerland, Italy, the Netherlands and France. This first medicine with which Techdow is entering our market has already been on sale in the UK and Germany, where it established itself in 2016.

Compounds based on low molecular weight heparin are a specialty of the Chinese pharmaceutical company, the first from China to introduce a medicine into Spain. The Spanish subsidiary of Shenzhen Techdow is headed up by Elena Sánchez as CEO. She stresses the high quality of its medicines and the extensive funds the company allocates to research.

The medical director of Techdow in Spain is Diego Vargas, who points to the cost of its first medicine, 20% lower than its competitors with the same indications, according to its European authorization obtained in 2016. The company is already preparing the launch of new medicines.